GENE THERAPY

metrics 2024

Exploring Breakthroughs in Genetic Research

Introduction

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

Metrics 2024

SCIMAGO Journal Rank1.67
Journal Impact Factor4.60
Journal Impact Factor (5 years)4.30
H-Index174
Journal IF Without Self4.60
Eigen Factor0.00
Normal Eigen Factor0.72
Influence1.22
Immediacy Index1.00
Cited Half Life13.10
Citing Half Life7.40
JCI0.98
Total Documents3899
WOS Total Citations6684
SCIMAGO Total Citations60754
SCIMAGO SELF Citations3638
Scopus Journal Rank1.67
Cites / Document (2 Years)5.33
Cites / Document (3 Years)4.86
Cites / Document (4 Years)4.50

Metrics History

Rank 2024

Scopus

Genetics in Biochemistry, Genetics and Molecular Biology
Rank #46/347
Percentile 86.74
Quartile Q1
Molecular Biology in Biochemistry, Genetics and Molecular Biology
Rank #81/410
Percentile 80.24
Quartile Q1
Molecular Medicine in Biochemistry, Genetics and Molecular Biology
Rank #37/178
Percentile 79.21
Quartile Q1

IF (Web Of Science)

BIOCHEMISTRY & MOLECULAR BIOLOGY
Rank 74/313
Percentile 76.50
Quartile Q1
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 31/174
Percentile 82.50
Quartile Q1
GENETICS & HEREDITY
Rank 35/191
Percentile 81.90
Quartile Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 49/189
Percentile 74.30
Quartile Q2

JCI (Web Of Science)

BIOCHEMISTRY & MOLECULAR BIOLOGY
Rank 73/313
Percentile 76.68
Quartile Q1
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 41/174
Percentile 76.44
Quartile Q1
GENETICS & HEREDITY
Rank 48/191
Percentile 74.87
Quartile Q2
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 50/189
Percentile 73.54
Quartile Q2

Quartile History

Similar Journals

CANCER GENE THERAPY

Innovating Genetic Solutions for Oncology
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

EXPERT REVIEWS IN MOLECULAR MEDICINE

Pioneering Reviews that Drive Molecular Research Forward
Publisher: CAMBRIDGE UNIV PRESSISSN: 1462-3994Frequency: 1 issue/year

EXPERT REVIEWS IN MOLECULAR MEDICINE, published by Cambridge University Press, stands at the forefront of research in the fields of Molecular Biology and Molecular Medicine. With an impressive impact factor reflecting its Q1 status in both relevant categories, this journal serves as an essential platform for disseminating cutting-edge reviews and critical assessments that are vital for advancing our understanding of molecular mechanisms in health and disease. Established in 1997 and continuously evolving until 2024, it features contributions from leading experts that highlight emerging trends and innovative methodologies. Researchers, professionals, and students are encouraged to engage with the content, benefiting from the journal’s rigorous peer-review process and its commitment to academic excellence, making it a valuable resource within the scientific community.

JOURNAL OF GENE MEDICINE

Empowering the Next Generation of Molecular Medicine
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

ImmunoTargets and Therapy

Empowering Research, Enhancing Lives
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

Cell Journal

Exploring Cellular Mysteries, Inspiring Innovations
Publisher: ROYAN INSTISSN: 2228-5806Frequency: 12 issues/year

Cell Journal is a leading interdisciplinary publication in the fields of Cell Biology, Developmental Biology, Molecular Biology, and Reproductive Medicine, published by ROYAN INST since its inception as an open-access journal in 2007. With an ISSN of 2228-5806 for print and 2228-5814 for electronic editions, it provides a vital platform for researchers and professionals to disseminate innovative findings and insights that shape our understanding of cellular processes and reproductive sciences. The journal boasts an impressive Scopus ranking, achieving a Q3 position in both Molecular Biology and Reproductive Medicine, highlighting its significance in the academic community. Situated in Tehran, Iran, Cell Journal encourages global collaboration through its accessible content, making cutting-edge research available to a diverse audience. As it converges from 2011 to 2024, the journal continues to emphasize the importance of thorough scientific inquiry, fostering advancements that drive both theoretical frameworks and practical applications in cell science.

CANCER CELL

Transforming Knowledge into Breakthrough Therapies
Publisher: CELL PRESSISSN: 1535-6108Frequency: 12 issues/year

Cancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Connecting academics to the pulse of molecular medicine.
Publisher: SPANDIDOS PUBL LTDISSN: 1107-3756Frequency: 12 issues/year

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Advancing cancer research through innovation and collaboration.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Journal of Hematology & Oncology

Pioneering Discoveries in Hematology and Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

JOURNAL OF MOLECULAR MEDICINE-JMM

Pioneering Insights in Drug Discovery and Genetics.
Publisher: SPRINGER HEIDELBERGISSN: 0946-2716Frequency: 12 issues/year

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.